Legis Daily

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

USA115th CongressHR-5247| House 
| Updated: 4/9/2018
Brian K. Fitzpatrick

Brian K. Fitzpatrick

Republican Representative

Pennsylvania

Cosponsors (44)
David Schweikert (Republican)Paul A. Gosar (Republican)Michael C. Burgess (Republican)Karen C. Handel (Republican)Mo Brooks (Republican)Roger Marshall (Republican)Gregg Harper (Republican)Mark Meadows (Republican)Rick W. Allen (Republican)Neal P. Dunn (Republican)John Abney Culberson (Republican)Marsha Blackburn (Republican)Ken Buck (Republican)John J. Faso (Republican)Leonard Lance (Republican)Andy Biggs (Republican)Jeff Duncan (Republican)Keith J. Rothfus (Republican)Earl L. "Buddy" Carter (Republican)Ken Calvert (Republican)Todd Rokita (Republican)J. French Hill (Republican)Dan Newhouse (Republican)Luke Messer (Republican)H. Morgan Griffith (Republican)Andy Barr (Republican)Darrell Issa (Republican)Doug Lamborn (Republican)Kyrsten Sinema (Independent)Steve King (Republican)Chris Collins (Republican)Kevin Cramer (Republican)Jason Lewis (Republican)Mike Gallagher (Republican)Diane Black (Republican)Ted S. Yoho (Republican)Vicky Hartzler (Republican)Bill Huizenga (Republican)Joe Barton (Republican)Randy K. Sr. Weber (Republican)Kevin Yoder (Republican)Jaime Herrera Beutler (Republican)Barbara Comstock (Republican)Vern Buchanan (Republican)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must publish annual summaries on any use of the drug in accordance with these provisions. The bill limits the liability of a sponsor, manufacturer, licensed physician, clinical investigator, or hospital that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 13, 2018
Introduced in House
Mar 13, 2018
Referred to the House Committee on Energy and Commerce.
Mar 13, 2018
Mr. Walden moved to suspend the rules and pass the bill.
Mar 13, 2018
Considered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)
Mar 13, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.
Mar 13, 2018
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Mar 13, 2018
Considered as unfinished business. (consideration: CR H1528-1529)
Mar 13, 2018
On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
View Vote
Mar 16, 2018
Referred to the Subcommittee on Health.
Mar 19, 2018
Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
Mar 20, 2018
Rule H. Res. 787 passed House.
Mar 21, 2018
Considered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)
Mar 21, 2018
The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
Mar 21, 2018
DEBATE - The House proceeded with one hour of debate on H.R. 5247.
Mar 21, 2018
The previous question was ordered pursuant to the rule.
Mar 21, 2018
Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)
Mar 21, 2018
DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.
Mar 21, 2018
The previous question on the motion to recommit with instructions was ordered without objection.
Mar 21, 2018
POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.
Mar 22, 2018
Considered as unfinished business. (consideration: CR H1748-1750)
Mar 22, 2018
On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).
View Vote
Mar 22, 2018
On passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)
View Vote
Mar 22, 2018
Motion to reconsider laid on the table Agreed to without objection.
Mar 22, 2018
Received in the Senate.
Mar 23, 2018
Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
Apr 9, 2018
Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.
May 30, 2018

Latest Companion Bill Action

S 115-204
Signed by President.
  • March 13, 2018
    Introduced in House


  • March 13, 2018
    Referred to the House Committee on Energy and Commerce.


  • March 13, 2018
    Mr. Walden moved to suspend the rules and pass the bill.


  • March 13, 2018
    Considered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)


  • March 13, 2018
    DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.


  • March 13, 2018
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • March 13, 2018
    Considered as unfinished business. (consideration: CR H1528-1529)


  • March 13, 2018
    On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
    View Vote


  • March 16, 2018
    Referred to the Subcommittee on Health.


  • March 19, 2018
    Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.


  • March 20, 2018
    Rule H. Res. 787 passed House.


  • March 21, 2018
    Considered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)


  • March 21, 2018
    The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.


  • March 21, 2018
    DEBATE - The House proceeded with one hour of debate on H.R. 5247.


  • March 21, 2018
    The previous question was ordered pursuant to the rule.


  • March 21, 2018
    Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)


  • March 21, 2018
    DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.


  • March 21, 2018
    The previous question on the motion to recommit with instructions was ordered without objection.


  • March 21, 2018
    POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.


  • March 22, 2018
    Considered as unfinished business. (consideration: CR H1748-1750)


  • March 22, 2018
    On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).
    View Vote


  • March 22, 2018
    On passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)
    View Vote


  • March 22, 2018
    Motion to reconsider laid on the table Agreed to without objection.


  • March 22, 2018
    Received in the Senate.


  • March 23, 2018
    Read the first time. Placed on Senate Legislative Calendar under Read the First Time.


  • April 9, 2018
    Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.


  • May 30, 2018

    Latest Companion Bill Action

    S 115-204
    Signed by President.

Health

Related Bills

  • HRES 115-787: Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.
  • S 115-204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Business recordsCivil actions and liabilityDrug safety, medical device, and laboratory regulationDrug therapyGovernment information and archivesLong-term, rehabilitative, and terminal careMedical researchPrescription drugs

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

USA115th CongressHR-5247| House 
| Updated: 4/9/2018
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must publish annual summaries on any use of the drug in accordance with these provisions. The bill limits the liability of a sponsor, manufacturer, licensed physician, clinical investigator, or hospital that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 13, 2018
Introduced in House
Mar 13, 2018
Referred to the House Committee on Energy and Commerce.
Mar 13, 2018
Mr. Walden moved to suspend the rules and pass the bill.
Mar 13, 2018
Considered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)
Mar 13, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.
Mar 13, 2018
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Mar 13, 2018
Considered as unfinished business. (consideration: CR H1528-1529)
Mar 13, 2018
On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
View Vote
Mar 16, 2018
Referred to the Subcommittee on Health.
Mar 19, 2018
Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
Mar 20, 2018
Rule H. Res. 787 passed House.
Mar 21, 2018
Considered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)
Mar 21, 2018
The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
Mar 21, 2018
DEBATE - The House proceeded with one hour of debate on H.R. 5247.
Mar 21, 2018
The previous question was ordered pursuant to the rule.
Mar 21, 2018
Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)
Mar 21, 2018
DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.
Mar 21, 2018
The previous question on the motion to recommit with instructions was ordered without objection.
Mar 21, 2018
POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.
Mar 22, 2018
Considered as unfinished business. (consideration: CR H1748-1750)
Mar 22, 2018
On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).
View Vote
Mar 22, 2018
On passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)
View Vote
Mar 22, 2018
Motion to reconsider laid on the table Agreed to without objection.
Mar 22, 2018
Received in the Senate.
Mar 23, 2018
Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
Apr 9, 2018
Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.
May 30, 2018

Latest Companion Bill Action

S 115-204
Signed by President.
  • March 13, 2018
    Introduced in House


  • March 13, 2018
    Referred to the House Committee on Energy and Commerce.


  • March 13, 2018
    Mr. Walden moved to suspend the rules and pass the bill.


  • March 13, 2018
    Considered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)


  • March 13, 2018
    DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.


  • March 13, 2018
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • March 13, 2018
    Considered as unfinished business. (consideration: CR H1528-1529)


  • March 13, 2018
    On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
    View Vote


  • March 16, 2018
    Referred to the Subcommittee on Health.


  • March 19, 2018
    Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.


  • March 20, 2018
    Rule H. Res. 787 passed House.


  • March 21, 2018
    Considered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)


  • March 21, 2018
    The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.


  • March 21, 2018
    DEBATE - The House proceeded with one hour of debate on H.R. 5247.


  • March 21, 2018
    The previous question was ordered pursuant to the rule.


  • March 21, 2018
    Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)


  • March 21, 2018
    DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.


  • March 21, 2018
    The previous question on the motion to recommit with instructions was ordered without objection.


  • March 21, 2018
    POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.


  • March 22, 2018
    Considered as unfinished business. (consideration: CR H1748-1750)


  • March 22, 2018
    On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).
    View Vote


  • March 22, 2018
    On passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)
    View Vote


  • March 22, 2018
    Motion to reconsider laid on the table Agreed to without objection.


  • March 22, 2018
    Received in the Senate.


  • March 23, 2018
    Read the first time. Placed on Senate Legislative Calendar under Read the First Time.


  • April 9, 2018
    Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.


  • May 30, 2018

    Latest Companion Bill Action

    S 115-204
    Signed by President.
Brian K. Fitzpatrick

Brian K. Fitzpatrick

Republican Representative

Pennsylvania

Cosponsors (44)
David Schweikert (Republican)Paul A. Gosar (Republican)Michael C. Burgess (Republican)Karen C. Handel (Republican)Mo Brooks (Republican)Roger Marshall (Republican)Gregg Harper (Republican)Mark Meadows (Republican)Rick W. Allen (Republican)Neal P. Dunn (Republican)John Abney Culberson (Republican)Marsha Blackburn (Republican)Ken Buck (Republican)John J. Faso (Republican)Leonard Lance (Republican)Andy Biggs (Republican)Jeff Duncan (Republican)Keith J. Rothfus (Republican)Earl L. "Buddy" Carter (Republican)Ken Calvert (Republican)Todd Rokita (Republican)J. French Hill (Republican)Dan Newhouse (Republican)Luke Messer (Republican)H. Morgan Griffith (Republican)Andy Barr (Republican)Darrell Issa (Republican)Doug Lamborn (Republican)Kyrsten Sinema (Independent)Steve King (Republican)Chris Collins (Republican)Kevin Cramer (Republican)Jason Lewis (Republican)Mike Gallagher (Republican)Diane Black (Republican)Ted S. Yoho (Republican)Vicky Hartzler (Republican)Bill Huizenga (Republican)Joe Barton (Republican)Randy K. Sr. Weber (Republican)Kevin Yoder (Republican)Jaime Herrera Beutler (Republican)Barbara Comstock (Republican)Vern Buchanan (Republican)

Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • HRES 115-787: Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.
  • S 115-204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCivil actions and liabilityDrug safety, medical device, and laboratory regulationDrug therapyGovernment information and archivesLong-term, rehabilitative, and terminal careMedical researchPrescription drugs